Search
Interviews with the world’s key opinion leaders in cancer

CategoryNews

Biomarkers individualise cancer therapy

Dr Escudier explained that the biomarkers identify patients who will respond to this targeted agent — music to the manufacturers’ ears, I’m sure! It is interesting in the context of individualising therapy, and raises questions which are...

Big orteronel study: prostate hopes

Robert Dreicer MD describes this negative finding which was nevertheless a fine study, indicating the value of large phase III investigations. Orteronel is similar in action to abiraterone, and there were responses: in the non-USA patients these...

Enzalutamide good after abiraterone

SAN FRANCISCO: Heather Cheng was very much in favour of using enzalutamide after abiraterone since her data show a 30 per cent response rate even in a third of patients who had not responded at all to abi, and higher proportions in both abi...

Ezalutamide — wider prostate benefit

SAN FRANCISCO—Dr Tomasz Beer, said their new data make a good case for using enzalutamide to treat prostate cancer in chemo-naïve patients. He spoke reassuringly about both efficacy and safety. Tomasz Beer MD, Oregon Health & Science...

‘Mediterranean diet’ protects against diabetes

The ‘Mediterranean diet’ — rich in fish, whole grains, fruit, and vegetables, and including moderate amounts of red wine — is widely believed to protect against a number of diseases. A new study has now tried settle the issue once and...

Quitting smoking cuts risk of cataract

A New Year article in JAMA Ophthalmology points out that smoking cessation can halve your risk of needing a cataract extraction later in life. The researchers looked at 40 000 Swedish men between the ages of 45 and 79 years and found there was a...